Having trouble reading this e-mail? View it in your browser.

Blue Benefits Bulletin

December 2009

Learn About Changes to the Preferred Drug List in 2010

Inline ImageThe Preferred Drug List (PDL) and other drug lists for 2010 are now available and can be reviewed in the Pharmacy section of bcbst.com.

Changes to the PDL for 2010
The following changes to the PDL will take effect Jan. 1, 2010, and are designed to help members and groups save money on prescription drugs. Because of the nature of the prescription drug market, additional changes may be made prior to Jan. 1, 2010.

The following generic (and branded generic) drugs will be added to Tier 1:            

  • brimonidine (Alphagan P)
  • budesonide inhalation (Pulmicort inhalation)
  • lansoprazole (Prevacid)
  • miglitol (Glyset-no longer on the market)
  • repaglinide (Prandin)
  • valacyclovir (Valtrex)

The following drugs will cost members less. They will move from Tier 3 (highest copay) to Tier 2 (lower copay):

  • Astepro (added Oct. 1, 2009)
  • Boniva
  • Bystolic (added Oct. 1, 2009)
  • Coreg CR (added Oct. 1, 2009)
  • Savella (added Oct. 1, 2009)                                        
  • Trilipix  (added Oct. 1, 2009)
  • Venlafaxine ER
  • Ventolin HFA

The following drugs will cost members more. They are moving from Tier 2 (lower copay) to Tier 3 (highest copay). Preferred brands (alternatives) may be available for these drugs, and generic equivalents are indicated in bold.

  • Alphagan P (brimonidine)
  • Atacand (Avapro, Benicar, Micardis)
  • Atacand HCT (Avalide, Benicar HCT, Micardis HCT)
  • Copaxone
  • Miacalcin (calcitonin-salmon)
  • Prevacid (lansoprazole; the 15mg will be OTC)
  • Proventil HFA (ProAir HFA, Ventolin HFA)
  • Rebif
  • Valtrex (valacyclovir)

The following drugs are being added to the Prior Authorization list:

  • Cimzia
  • Enbrel
  • Humira
  • Kineret
  • Nuvigil
  • Provigil
  • Simponi

The PDL is reviewed annually to determine needed changes based on drugs’ clinical effectiveness, safety and affordability. This review includes an analysis to determine a long-term “Lowest Net Cost” for members and groups.

While many changes to the PDL occur at the beginning of the year, drugs on the PDL can change throughout the year due to market changes such as:

  • Release of new drugs to the market after FDA approval;
  • Removal of drugs from the market by the FDA; and
  • Release of new generic drugs to the market

For the most up-to-date information on prescription drugs, visit the Pharmacy section of bcbst.com.

 
 
Footer